vs
Immunovant, Inc.（IMVT）与Valaris Ltd（VAL）财务数据对比。点击上方公司名可切换其他公司
Immunovant, Inc.的季度营收约是Valaris Ltd的1.6倍（$8.4M vs $5.2M），Valaris Ltd净利率更高（13798.1% vs -899.0%，领先14697.1%），Valaris Ltd同比增速更快（405.9% vs 140.7%），Valaris Ltd自由现金流更多（$-34.1M vs $-59.8M）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
瓦拉瑞斯有限公司是全球领先的海上钻井承包商，总部位于美国得克萨斯州休斯敦，注册地为百慕大，是全球规模最大的海上钻井及油井钻井服务企业。截至2025年2月，公司共运营52座钻井平台，包含36座海上自升式钻井平台、11艘钻井船以及5座半潜式钻井平台。
IMVT vs VAL — 直观对比
营收规模更大
IMVT
是对方的1.6倍
$5.2M
营收增速更快
VAL
高出265.1%
140.7%
净利率更高
VAL
高出14697.1%
-899.0%
自由现金流更多
VAL
多$25.7M
$-59.8M
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $5.2M |
| 净利润 | $-75.3M | $717.5M |
| 毛利率 | — | -7850.0% |
| 营业利润率 | -896.2% | — |
| 净利率 | -899.0% | 13798.1% |
| 营收同比 | 140.7% | 405.9% |
| 净利润同比 | -26.7% | 436.6% |
| 每股收益（稀释后） | $-0.50 | $10.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTVAL
| Q4 25 | — | $5.2M | ||
| Q3 25 | — | $5.6M | ||
| Q2 25 | — | $700.0K | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $4.8M | ||
| Q1 24 | $8.4M | $2.6M | ||
| Q4 23 | $8.9M | $3.1M |
净利润IMVTVAL
| Q4 25 | — | $717.5M | ||
| Q3 25 | — | $188.1M | ||
| Q2 25 | — | $115.1M | ||
| Q4 24 | — | $133.7M | ||
| Q3 24 | — | $64.6M | ||
| Q2 24 | — | $149.6M | ||
| Q1 24 | $-75.3M | $25.5M | ||
| Q4 23 | $-51.4M | $828.5M |
毛利率IMVTVAL
| Q4 25 | — | -7850.0% | ||
| Q3 25 | — | -7142.9% | ||
| Q2 25 | — | -56428.6% | ||
| Q4 24 | — | 24529.4% | ||
| Q3 24 | — | -11748.7% | ||
| Q2 24 | — | -9039.6% | ||
| Q1 24 | — | -17007.7% | ||
| Q4 23 | — | -12867.7% |
营业利润率IMVTVAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -896.2% | — | ||
| Q4 23 | -576.8% | — |
净利率IMVTVAL
| Q4 25 | — | 13798.1% | ||
| Q3 25 | — | 3358.9% | ||
| Q2 25 | — | 16442.9% | ||
| Q4 24 | — | -7864.7% | ||
| Q3 24 | — | 1656.4% | ||
| Q2 24 | — | 3116.7% | ||
| Q1 24 | -899.0% | 980.8% | ||
| Q4 23 | -575.6% | 26725.8% |
每股收益（稀释后）IMVTVAL
| Q4 25 | — | $10.13 | ||
| Q3 25 | — | $2.65 | ||
| Q2 25 | — | $1.61 | ||
| Q4 24 | — | $1.86 | ||
| Q3 24 | — | $0.88 | ||
| Q2 24 | — | $2.03 | ||
| Q1 24 | $-0.50 | $0.35 | ||
| Q4 23 | $-0.36 | $11.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | $599.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $617.8M | $3.2B |
| 总资产 | $666.4M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMVTVAL
| Q4 25 | — | $599.4M | ||
| Q3 25 | — | $662.7M | ||
| Q2 25 | — | $503.4M | ||
| Q4 24 | — | $368.2M | ||
| Q3 24 | — | $379.3M | ||
| Q2 24 | — | $398.3M | ||
| Q1 24 | $635.4M | $494.1M | ||
| Q4 23 | $690.9M | $620.5M |
股东权益IMVTVAL
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.3B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | $617.8M | $2.0B | ||
| Q4 23 | $679.3M | $2.0B |
总资产IMVTVAL
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $4.6B | ||
| Q2 25 | — | $4.5B | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | $666.4M | $4.4B | ||
| Q4 23 | $711.4M | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | $72.2M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $-34.1M |
| 自由现金流率自由现金流/营收 | -714.4% | -655.8% |
| 资本支出强度资本支出/营收 | 1.8% | 2044.2% |
| 现金转化率经营现金流/净利润 | — | 0.10× |
| 过去12个月自由现金流最近4个季度 | $-214.6M | $159.9M |
8季度趋势，按日历期对齐
经营现金流IMVTVAL
| Q4 25 | — | $72.2M | ||
| Q3 25 | — | $198.1M | ||
| Q2 25 | — | $120.0M | ||
| Q4 24 | — | $124.6M | ||
| Q3 24 | — | $193.0M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | $-59.7M | $26.3M | ||
| Q4 23 | $-47.1M | $96.7M |
自由现金流IMVTVAL
| Q4 25 | — | $-34.1M | ||
| Q3 25 | — | $128.3M | ||
| Q2 25 | — | $52.8M | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | — | $111.1M | ||
| Q2 24 | — | $-98.7M | ||
| Q1 24 | $-59.8M | $-125.0M | ||
| Q4 23 | $-47.2M | $-366.3M |
自由现金流率IMVTVAL
| Q4 25 | — | -655.8% | ||
| Q3 25 | — | 2291.1% | ||
| Q2 25 | — | 7542.9% | ||
| Q4 24 | — | -758.8% | ||
| Q3 24 | — | 2848.7% | ||
| Q2 24 | — | -2056.3% | ||
| Q1 24 | -714.4% | -4807.7% | ||
| Q4 23 | -528.7% | -11816.1% |
资本支出强度IMVTVAL
| Q4 25 | — | 2044.2% | ||
| Q3 25 | — | 1246.4% | ||
| Q2 25 | — | 9600.0% | ||
| Q4 24 | — | -6570.6% | ||
| Q3 24 | — | 2100.0% | ||
| Q2 24 | — | 2295.8% | ||
| Q1 24 | 1.8% | 5819.2% | ||
| Q4 23 | 1.5% | 14935.5% |
现金转化率IMVTVAL
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 1.04× | ||
| Q4 24 | — | 0.93× | ||
| Q3 24 | — | 2.99× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 1.03× | ||
| Q4 23 | — | 0.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
